SCHEMBL31401675

SCHEMBL31401675

CC(C)(C)OC(=O)NC1CN(C(=O)O)CCC2CCCN2C1=O

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 3/20 0.45
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.39
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
PRSS1 P07477 1/20 0.38
CTSK P43235 2/20 0.38
CYP2C9 P11712 1/20 0.37
HSD11B1 P28845 1/20 0.37
BTK Q06187 1/20 0.37
RAMP1 O60894 3/20 0.36
CALCRL Q16602 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597028 0.87 FPR2 (0.54) FPR2CA1CA2GAAF2
SCHEMBL13399243 0.85 FPR2 (0.46) FPR2CA1CA2KMT2AL3MBTL1
SCHEMBL33525505 0.85 FPR2 (0.46) FPR2CA1CA2KMT2AL3MBTL1
SCHEMBL12185691 0.85 FPR2 (0.46) FPR2CA1CA2KMT2AL3MBTL1
SCHEMBL33525685 0.85 FPR2 (0.46) FPR2CA1CA2KMT2AL3MBTL1
SCHEMBL25867492 0.82 F2 (0.45) FPR2CA1CA2KMT2AL3MBTL1
SCHEMBL31291969 0.81 FPR2 (0.50) FPR2CA1CA2KMT2AL3MBTL1
SCHEMBL23833011 0.81 XIAP (0.42) CA1CA2
SCHEMBL13675582 0.80 FPR2 (0.49) FPR2CA1CA2KMT2AL3MBTL1
SCHEMBL33525732 0.80 FPR2 (0.51) FPR2CA1CA2KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059221-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059221-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 FPR2 4052/4885CA1 2752/4885CA2 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.